Tylenol lifts J&J's OTC business in the US

16 April 2019 - Deborah Wilkes

Premium

Johnson & Johnson's (J&J's) OTC business in the US reported sales up by almost a tenth during the first quarter of 2019, following market share gains for Tylenol analgesics and the acquisition of natural health specialist Zarbee's.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: